Petrichor Capital Partners

Petrichor Capital Partners is a private equity firm specializing in structured investments within the healthcare sector. Founded in 2018, the firm focuses on biopharmaceuticals, medical technology, diagnostics, and healthcare services, providing growth capital to companies at various stages of development. Their investment approach is characterized by a deep in-house understanding of scientific, technical, and commercial aspects, enabling them to identify and support innovative healthcare solutions.

The firm's investment strategy encompasses early-stage, growth, and late-stage opportunities, with investment sizes ranging from $10 million to $50 million. Petrichor Capital Partners has a strong track record, having completed over 125 investments representing more than $6 billion in invested capital and holding over 55 board seats. Their portfolio includes companies such as LumiraDx, Cryoport, CorneaGen, Persivia, and ClearPoint Neuro.

Petrichor Capital Partners is headquartered in New York City, with a team of experienced professionals dedicated to fostering the development and commercial growth of healthcare innovations. Their strategic approach and industry expertise position them as a significant player in the healthcare private equity landscape.